Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $216.04, with a market capitalization of 31.94B. The stock trades at a price-to-earnings (P/E) ratio of 38.37.
During the trading session on 2026-09-01, Biogen(BIIB) shares reached a daily high of $219.30 and a low of $213.60. At a current price of $216.04, the stock is +1.1% higher than the low and still -1.5% under the high.
Trading volume for Biogen(BIIB) stock has reached 742.04K, versus its average volume of 675.05K.
The stock's 52-week range extends from a low of $133.53 to a high of $222.85.
The stock's 52-week range extends from a low of $133.53 to a high of $222.85.
BIIB News
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support t...
Biogen (NasdaqGS:BIIB) announced the launch of LEQEMBI IQLIK, a once weekly subcutaneous autoinjector for early Alzheimer's disease, offering at home treatment...
Analyst ratings
67%
of 36 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.